DAIC

JANUARY 7, 2025

FIRE1s Norm heart failure management system offers a unique approach for patients to manage heart failure. The Norm heart failure self-management system is a first-of-its-kind innovation that empowers patients to take greater control of their health.

Heart Failure 64

Heart Failure Chronic Disease Innovation Technology 64

DAIC

MAY 6, 2024

We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano , President & Chief Executive Officer of Tenax Therapeutics. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

DAIC

FEBRUARY 12, 2024

Barostim is the world’s first FDA-approved neuromodulation heart failure device, which works by stimulating baroreceptors — natural sensors located in the wall of the carotid artery, according to CVRx. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Heart Failure 104

Heart Failure Hospital Quality of Life Heart Attack 104

Frontiers in Cardiovascular Medicine

JANUARY 31, 2025

IntroductionVentricular assist devices (VADs) are lifesavers for people with advanced heart failure. These data are crucial for driving innovation in this field and for improving the lives of patients who depend on VADs.

Document 80

Document Innovation Heart Failure Technology 80

DAIC

FEBRUARY 10, 2025

Additionally, the algorithm demonstrated its ability to pinpoint specific, clinically relevant segments of heart sound recordings, offering a transparent and explainable AI approach that aligns with physicians diagnostic workflows. The companys goal is to develop pioneering AI solutions that address significant gaps in healthcare delivery.

Research 64

Research Innovation Pulmonary Hypertension 64

DAIC

FEBRUARY 15, 2024

(AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF). It is estimated that 26 million worldwide are living with congestive heart failure.

Heart Failure 89

Heart Failure Cardiomyopathy Quality of Life Innovation 89

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

HCPLive

AUGUST 27, 2024

Allegheny Health Network (AHN) implants innovative device to manage central sleep apnea in heart failure patients, reducing mortality rise and improving quality of life.

Innovation 40

Innovation Heart Failure Quality of Life 40

DAIC

FEBRUARY 14, 2025

The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (Echo) markers of diastolic dysfunction, an important component in the development of heart failure, in hypertensive patients. Advanced Heart Failure Cardiologist, Duke Health on Feb.

Blood Pressure 52

Blood Pressure Heart Failure Hypertension Technology 52

Becker's Hospital Review - Cardiology

AUGUST 19, 2024

"Discover the latest innovation in heart failure screening with an at-home testing device created by Colorado State University. Learn more at the American Chemi

Heart Failure 52

Heart Failure Research Innovation 52

American College of Cardiology

NOVEMBER 5, 2024

The idea that obesity increases the risk of heart failure seems like an obvious conclusion. After all, as the Framingham Heart Study clearly showed, obesity and overweight are significantly associated with a higher risk of hypertension, angina and coronary heart disease.

Heart Failure 45

Heart Failure Innovation Angina Obesity 45

DAIC

JULY 29, 2024

mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth.

Innovation 105

Innovation Aortic valve Aortic CMS 105

DAIC

MARCH 5, 2024

Early Feasibility Study (FUTURE-HF2) of its FIRE1 System for remote heart failure monitoring. The FIRE1 System is the first device designed to directly measure a patient’s volume status by measuring the largest vein in the body where most fluid is stored – the inferior vena cava (IVC) – to better manage heart failure.

Heart Failure 52

Heart Failure Innovation Hospital Technology 52

HCPLive

MARCH 14, 2024

The AccuCinch® System, utilized by Allegheny General Hospital, offers a breakthrough approach to treating heart failure by targeting the left ventricle.

Quality of Life 52

Quality of Life Heart Failure Cardiac Function Innovation 52

DAIC

MAY 3, 2024

Clinical trials and innovative technology took center stage during the month of April, racking up some record number views. 24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack 10. Here is a look at what DAIC viewers were reading last month: 1. EMPACT-MI Trial Outcomes Reported at ACC.24:

Blood Pressure 105

Blood Pressure Angioplasty Heart Attack Heart attacks 105

DAIC

MAY 17, 2024

Based on the Health Data Hub complete medico-administrative database and comprehensive datasets from Implicity's AI -based remote monitoring platform, the Implicity team trained and validated a machine learning algorithm that assesses the risk of future heart failure events, enabling physicians to intervene before a patient requires hospitalization.

Heart Failure 52

Heart Failure Pacemaker Hospital Defibrillator 52

Frontiers in Cardiovascular Medicine

JANUARY 10, 2024

Ischemic heart disease (IHD) is one of the world's foremost killers, accounting for 16% of all deaths worldwide. IHD is the main cause of heart failure (HF), as it leads to pathological changes in the heart, improper pumping function and eventual death.

Heart Failure 59

Heart Failure Academic COVID-19 Innovation 59

DAIC

MARCH 8, 2024

suffer from heart failure , and there are approximately 400,000 heart-failure-related deaths in this country each year. Patients with heart failure often experience reduced mobility, quality of life and ability to work; the disease also represents a significant public health care burden.

Blood Clot 98

Blood Clot Heart Failure Quality of Life Innovation 98

DAIC

JUNE 5, 2024

The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure. Critical Care has made significant contributions to our company and has a long history of pioneering innovation.

Critical Care 105

Critical Care Tricuspid Innovation Bicuspid/Mitral 105

DAIC

MAY 30, 2024

milla1cf Thu, 05/30/2024 - 10:31 May 30, 2024 — Stereotaxis , a pioneer in surgical robotics for minimally invasive endovascular intervention, announced the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System.

Technology 105

Technology Heart Rhythm Hospital Cardiac Arrest 105

DAIC

FEBRUARY 21, 2024

However, there is a notable gap in device options for infants and young children with end stage heart failure. Although tools for the youngest heart patients are limited, the Ochsner Children’s Hospital team provides top-of-the-line care to bridge patients safely to transplant and a hope for a better quality of life.

Pediatrics 105

Pediatrics Hospital Heart Failure Transplant 105

DAIC

DECEMBER 18, 2024

12, 2024 Physicians have a new treatment option for many of the sickest pediatric patients with heart failure andcardiogenic shock. and Impella CP enable heart recovery as part of the world's smallest heart pump platform. with SmartAssist tim.hodson Wed, 12/18/2024 - 14:06 Dec.

Pediatrics 52

Pediatrics Cardiogenic Shock Heart Failure Quality of Life 52

DAIC

JANUARY 15, 2024

Cardiac amyloidosis is a heterogeneous disease that results from the accumulation of abnormal proteins within the heart, impairing its ability to pump blood. Over time, the build-up of these proteins causes the heart muscle to stiffen, eventually leading to heart failure, which can have dire outcomes if not found early.

Ultrasound 119

Ultrasound Coronary Artery Disease Innovation Heart Failure 119

DAIC

FEBRUARY 18, 2025

Catheter-based procedures offer an alternative for patients who are not candidates for open-heart surgery. Studies estimate that severe regurgitation occurs in up to 4% of individuals 75 and older and is often linked with conditions like heart failure, atrial fibrillation or pulmonary hypertension.

Tricuspid 52

Tricuspid Open-Heart Surgery Quality of Life Anatomy 52

Circulation: Genomic and Precision Medicine

MAY 20, 2024

In this review, we present the available literature reporting omics data on heart failure that can inform the development of novel treatments or innovative treatment strategies for this disease. Examples of omics data include genomics, transcriptomics, epigenomics, proteomics, metabolomics, and more.

Heart Failure 40

Heart Failure Innovation Circulation 40

DAIC

JANUARY 5, 2024

Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study Atrial Fibrillation Market Reaches $20.92B, According to New Report 9. Medtronic Receives FDA Approval for its Next Generation Micra Leadless Pacing Systems 10.

Atrial Fibrillation 105

Atrial Fibrillation Aortic valve Cardiothoracic Interventional Cardiology 105

DAIC

JUNE 11, 2024

Tricuspid and mitral valves are debilitating conditions that can lead to arrhythmias, hypertension, and heart failure. Until recently, therapeutic options for people with tricuspid and mitral valve disorders have been limited to symptom relief or high-risk surgery.

Tricuspid 111

Tricuspid Bicuspid/Mitral Heart Valves Innovation 111

DAIC

APRIL 23, 2024

milla1cf Tue, 04/23/2024 - 15:53 April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body.

Aortic valve 111

Aortic valve Aortic Innovation Cardiothoracic 111

DAIC

FEBRUARY 14, 2025

Amputation statistics are bleak, and amputation should be a last resort, said Dr. Shishehbor, President of UH Harrington Heart & Vascular Institute, and Angela and James Hambrick Chair in Innovation at UH. This is why we are passionate about pursuing alternatives to amputation for our patients. When we save a limb, we save a life.

Peripheral Arterial Disease 52

Peripheral Arterial Disease Cancer Innovation Best Practices 52

European Journal of Heart Failure

DECEMBER 19, 2024

BNP, B-type natriuretic peptide; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular filtration rate; EP, endpoint; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SwedeHF, Swedish Heart Failure Registry; US, United States.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Atrial Fibrillation Outpatient 40

CardiacWire

FEBRUARY 21, 2025

Competition breeds innovation, and thats good news for ATTR-CM patients who could have three different drugs to choose from: Vyndaqel (Pfizer), Attruby/Beyonttra (BridgeBio), and Amvuttra (Alnylam). The disease occurs when misfolded proteins build up in the heart and stiffen the heart muscle, leading to heart failure.

Innovation 59

Innovation Heart Failure Research Outcomes 59

DAIC

FEBRUARY 12, 2024

A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. and Allina Health. and Allina Health. and Allina Health.

Heart Failure 52

Heart Failure Hospital Quality of Life Heart Attack 52

DAIC

JUNE 13, 2024

Getty Images milla1cf Thu, 06/13/2024 - 20:38 June 13, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body.

Aortic valve 109

Aortic valve Aortic Innovation Cardiothoracic 109

DAIC

JULY 12, 2024

Lead researcher Dr Pankaj Garg , of the University of East Anglia’s Norwich Medical School and a consultant cardiologist at the Norfolk and Norwich University Hospital, heads up a team of researchers who have pioneered innovative and revolutionary 4D MRI imaging technology.

Outcomes 122

Outcomes Hospital Research Innovation 122

DAIC

FEBRUARY 1, 2024

The article also includes links to DAIC channels (on peripheral artery disease, stroke, heart failure, peripheral artery disease, cardiovascular clinical studies, and more) focused on specific areas of news coverage. People with diabetes are twice as likely to have heart disease or a stroke than people without diabetes. -

Cardiovascular Disease 104

Cardiovascular Disease Atherosclerosis Strokes Stroke 104

DAIC

MAY 21, 2024

milla1cf Tue, 05/21/2024 - 08:00 May 21, 2024 — Stereotaxis , a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has been invited to present at HRS Africa Summit 2024 , scheduled to take place during Heart Rhythm Society Scientific Sessions in Boston, Massachusetts.

Heart Rhythm 52

Heart Rhythm Innovation Electrophysiology Technology 52

Journal of Cardiovascular Pharmacology

OCTOBER 9, 2023

Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent one of the most important pharmacological innovations in the field of Cardiology of the last decades, having shown significant outcome improvement in all the heart failure (HF) spectrum. However, cost-effectiveness considerations should be made.

Heart Failure 40

Heart Failure Pharmacology Innovation Outcomes 40